良性前列腺增生治療市場規模、佔有率及成長分析（治療方法、類型、產品、最終用戶及地區分類）－2026-2033年產業預測

全球良性前列腺增生治療市場規模預計在 2024 年達到 120.8 億美元，從 2025 年的 127.4 億美元成長到 2033 年的 195.6 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

全球良性前列腺增生（BPH）治療市場受多種關鍵因素驅動。人口老化導致BPH盛行率不斷上升，使得尋求有效治療方法的患者群體日益擴大。這推動了對創新微創治療方法的需求，例如經尿道前列腺切除術、雷射治療和前列腺動脈栓塞術，這些療法有望縮短恢復時間並減少併發症。透過公共衛生措施和宣傳宣傳活動提高大眾對BPH的認知，進一步促進了早期診斷和治療，從而導致對各種治療方案的需求激增。此外，政府的支持性政策和優惠的報銷制度也推動了先進BPH治療方法，對市場擴張產生了正面影響。

推動全球良性前列腺增生治療市場發展的因素

人們對良性前列腺增生（BPH）及其相關症狀的認知不斷提高，促進了該疾病的早期發現和診斷。這種認知的提升得益於政府、醫療機構和計劃團體共同進行的宣傳宣傳活動和篩檢計畫。對及時介入和有效治療的重視不僅改善了患者的預後，也對BPH治療市場的擴張起到了關鍵作用。隨著人們對自身健康的了解和關注度不斷提高，對有效治療方法的需求顯著成長，進一步推動了市場發展。

限制全球良性前列腺增生治療市場的因素

由於專利到期，學名藥的湧入，全球良性前列腺增生（BPH）治療市場面臨嚴峻挑戰。這些學名藥，包括α受體阻斷劑和5α還原酶抑制劑，加劇了市場競爭，並對品牌藥的價格造成下行壓力。隨著越來越多的患者選擇這些經濟實惠的替代療法，現有品牌藥的市場收入可能會下降。這種價格承受能力的變化不僅影響消費者的選擇，也改變了市場競爭的整體動態，最終對BPH治療領域現有治療方法的盈利構成威脅。

良性攝護腺增生治療市場的全球趨勢

全球良性前列腺增生 (BPH) 治療市場正經歷著向微創手術的顯著轉變，這反映了更廣泛的醫療保健趨勢，即更加重視患者舒適度和治療效果。雷射消熔、經尿道前列腺切除術術 (TURP) 和前列腺尿道提升術 (PUL) 等技術因其諸多優勢而迅速被接受，這些優勢包括恢復時間更短、住院時間更短以及術後併發症率更低。這種對微創治療方法的重視源於對以患者為中心的護理理念的日益關注，旨在提高 BPH 患者的生活品質 (QOL)，同時有效控制醫療成本。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球良性前列腺增生治療市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 微創手術
• 侵入性手術

全球良性前列腺增生治療市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 藥物治療
  • α受體阻斷劑
  • 阿夫唑嗪
  • 多沙唑嗪
  • Tamsulosin
  • 西洛多辛
  • 其他α受體阻斷劑
  • 5α-還原酶抑制劑
  • 非那雄胺
  • 度他雄胺
  • 其他藥物類別
• 手術治療
  • 經尿道膀胱鏡攝護腺切除術（TURP）
  • 經尿道微波熱療（TUMT）
  • 經尿道針消融術（TUNA）
  • 雷射療法
  • 攝護腺支架置入術
  • Urolift療法
  • 瑞祖姆療法
  • 其他手術

全球良性前列腺增生治療市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 電切鏡
• 泌尿系統雷射
• 射頻消融術
• 電極
• 導管
• 攝護腺支架
• 植入
• 其他

全球良性前列腺增生治療市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 家庭醫療保健
• 醫院和診所
• 研究與製造

全球良性前列腺增生治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Boston Scientific Corporation（USA）
• Pfizer Inc.（USA）
• GlaxoSmithKline plc（UK）
• Eli Lilly and Company（USA）
• Abbott Laboratories（USA）
• Astellas Pharma Inc.（Japan）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• Teleflex Incorporated（USA）
• Olympus Corporation（Japan）
• Coloplast Group（Denmark）
• Asahi Kasei Corporation（Japan）
• Allergan plc（Ireland）
• IPG Photonics Corporation（USA）
• Richard Wolf GmbH（Germany）
• Biolitec AG（Austria）
• Urologix, LLC（USA）
• Procept BioRobotics Corporation（USA）
• Lumenis Ltd.（Israel）
• KARL STORZ SE & Co. KG（Germany）

結論與建議

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 12.08 Billion in 2024 and is poised to grow from USD 12.74 Billion in 2025 to USD 19.56 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global market for benign prostatic hyperplasia (BPH) treatment is being driven by several key factors. An increase in the prevalence of BPH, attributed to a growing aging population, has expanded the patient demographic seeking effective solutions. This has spurred demand for innovative and minimally invasive treatments, such as transurethral resection of the prostate, laser therapy, and prostatic artery embolization, which offer shorter recovery times and reduced complications. Enhanced awareness of BPH through public health initiatives and educational campaigns has further contributed to early diagnosis and treatment, resulting in a surge in demand for various treatment options. Additionally, supportive government policies and favorable reimbursement frameworks are boosting the adoption of advanced BPH therapies, positively influencing market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Benign Prostatic Hyperplasia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Benign Prostatic Hyperplasia Treatment Market Segments Analysis

Global Benign Prostatic Hyperplasia Treatment Market is segmented by Treatment, Type, Product, End User and region. Based on Treatment, the market is segmented into Minimal Invasive Surgery and Invasive Surgery. Based on Type, the market is segmented into Drug Treatment and Surgical Treatment. Based on Product, the market is segmented into Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants and Others. Based on End User, the market is segmented into Home Healthcare, Hospitals & Clinics and Research & Manufacturing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Benign Prostatic Hyperplasia Treatment Market

The increasing awareness surrounding benign prostatic hyperplasia (BPH) and its related symptoms is facilitating earlier detection and diagnosis. This heightened understanding is driven by the concerted efforts of governments, healthcare organizations, and advocacy groups, which are implementing campaigns and screening programs to raise awareness about the condition. The focus on prompt intervention and effective treatment not only enhances patient outcomes but also plays a crucial role in the expansion of the BPH treatment market. As individuals become more informed and proactive regarding their health, the demand for effective therapies significantly increases, further fueling market growth.

Restraints in the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia Treatment market faces significant restraints due to the expiration of patents, which has enabled the introduction of generic medications. These generics, including alpha-blockers and 5-alpha reductase inhibitors, have created a competitive environment that places downward pressure on the pricing of branded products. As patients increasingly opt for these cost-effective alternatives, market revenues for established brands may decline. This shift towards affordability not only impacts consumer choices but also alters the overall dynamics of market competition, ultimately challenging the profitability of existing treatment options in the BPH sector.

Market Trends of the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia (BPH) Treatment market is witnessing a significant shift towards minimally invasive procedures, reflecting a broader trend in healthcare prioritizing patient comfort and outcomes. Techniques such as laser ablation, transurethral resection of the prostate (TURP), and prostatic urethral lift (PUL) are rapidly gaining acceptance due to their advantages, including shorter recovery times, reduced hospital stays, and a lower incidence of postoperative complications. This emphasis on less invasive treatment options is fueled by a growing commitment to patient-centered care, which aims to enhance the overall quality of life for individuals suffering from BPH, while simultaneously addressing the imperative to manage healthcare costs effectively.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Benign Prostatic Hyperplasia Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Minimal Invasive Surgery
• Invasive Surgery

Global Benign Prostatic Hyperplasia Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Drug Treatment
  • Alpha Blockers
  • Alfuzosin
  • Doxazosin
  • Tamsulosin
  • Silodosin
  • Other Alpha Blockers
  • 5-Aplha Reductase Inhibitors
  • Finasteride
  • Dutasteride
  • Other Drug Classes
• Surgical Treatment
  • Transurethral Resection of the Prostate (TURP)
  • Transurethral Microwave Thermotherapy (TUMT)
  • Transurethral Needle Ablation of the Prostate (TUNA)
  • Laser Therapy
  • Prostatic Stenting
  • UroLift Therapy
  • Rezum Therapy
  • Other Surgeries

Global Benign Prostatic Hyperplasia Treatment Market Size by Product & CAGR (2026-2033)

• Market Overview
• Resectoscopes
• Urology Laser
• Radiofrequency Ablation
• Electrodes
• Catheters
• Prostatic Stents
• Implants
• Others

Global Benign Prostatic Hyperplasia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Home Healthcare
• Hospitals & Clinics
• Research & Manufacturing

Global Benign Prostatic Hyperplasia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment, Type, Product, End User)
  • US
  • Canada
• Europe (Treatment, Type, Product, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Product, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Product, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Product, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast Group (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IPG Photonics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Richard Wolf GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biolitec AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Urologix, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Procept BioRobotics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KARL STORZ SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations